Reduction in 3-Year Risk of Death or Lung Transplantation for Individuals with Advanced CF Lung Disease Treated with Elexacaftor/Tezacaftor/Ivacaftor

Affiliations

• ¹ St Paul's Hospital, Adult Cystic Fibrosis Clinic, Vancouver, British Columbia, Canada.
• ² The University of British Columbia Centre for Heart Lung Innovation, School of Population and Public Health, Vancouver, British Columbia, Canada.
• ³ Cystic Fibrosis Canada, Toronto, Ontario, Canada.
• ⁴ St. Michael's Hospital , Division of Respirology, Adult Cystic Fibrosis Centre, Toronto, Ontario, Canada.
• ⁵ University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
• ⁶ St Michael's Hospital Keenan Research Centre for Biomedical Science, Toronto, Ontario, Canada.
• ⁷ University of Toronto Temerty Faculty of Medicine, Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.
• ⁸ Dalhousie University Department of Community Health and Epidemiology, Halifax, Nova Scotia, Canada.
• ⁹ The University of British Columbia Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada.
• ¹⁰ The University of British Columbia - Vancouver Campus, Medicine, Vancouver, British Columbia, Canada.
• ¹¹ University College Dublin - National University of Ireland, Dublin, Ireland.
• ¹² University of British Columbia, Department of Medicine, Vancouver, British Columbia, Canada.
• ¹³ St Paul's Hospital, Adult Cystic Fibrosis Clinic, Vancouver, British Columbia, Canada; [email protected].